866-997-4948(US-Canada Toll Free)

Insomnia-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 99 Pages

Insomnia-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Insomnia-Pipeline Review, H2 2017, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Insomnia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 5, 9, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Insomnia-Overview 6
Insomnia-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Insomnia-Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Insomnia-Companies Involved in Therapeutics Development 22
Alexza Pharmaceuticals Inc 22
Athenex Inc 22
Eisai Co Ltd 22
Evotec AG 23
Grupo Ferrer Internacional SA 23
Heptares Therapeutics Ltd 24
Idorsia Ltd 24
Intec Pharma Ltd 24
Intra-Cellular Therapies Inc 25
Johnson & Johnson 25
Leading BioSciences Inc 26
Merck & Co Inc 26
Neurim Pharmaceuticals Ltd 27
Reviva Pharmaceuticals Inc 27
Shionogi & Co Ltd 28
Taisho Pharmaceutical Holdings Co Ltd 28
Yangtze River Pharmaceutical Group 29
Insomnia-Drug Profiles 30
(diphenhydramine + lorazepam + zolpidem tartrate)-Drug Profile 30
ACT-541468-Drug Profile 31
CB-2810-Drug Profile 33
CY-18-Drug Profile 34
CY-20-Drug Profile 35
DORA-12-Drug Profile 36
DRGT-73-Drug Profile 37
Drug for Insomnia-Drug Profile 38
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia-Drug Profile 39
EVT-201-Drug Profile 40
HTL-6641-Drug Profile 41
JNJ-48816274-Drug Profile 42
LASSBio-785-Drug Profile 43
LASSBio-786-Drug Profile 44
lemborexant-Drug Profile 45
lorediplon-Drug Profile 47
lumateperone tosylate-Drug Profile 49
MK-8133-Drug Profile 60
MLS-03-Drug Profile 61
nebivolol-Drug Profile 62
NEO-1940-Drug Profile 63
piromelatine-Drug Profile 64
S-117957-Drug Profile 66
seltorexant-Drug Profile 67
Small Molecule for Insomnia, Obesity and Treatment Resistant Depression-Drug Profile 72
Small Molecules to Activate CYP1A2 for Insomnia and Anxiety-Drug Profile 73
Small Molecules to Agonize CB1 and CB2 for Autism, Dermatitis and Insomnia-Drug Profile 74
Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia-Drug Profile 75
TS-142-Drug Profile 76
UCM-765-Drug Profile 77
zaleplon-Drug Profile 78
zaleplon-Drug Profile 79
zolpidem tartrate-Drug Profile 81
zolpidem tartrate-Drug Profile 82
Insomnia-Dormant Projects 83
Insomnia-Discontinued Products 85
Insomnia-Product Development Milestones 86
Featured News & Press Releases 86
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 95
Disclaimer 96

List of Tables
Number of Products under Development for Insomnia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Insomnia-Pipeline by Alexza Pharmaceuticals Inc, H2 2017
Insomnia-Pipeline by Athenex Inc, H2 2017
Insomnia-Pipeline by Eisai Co Ltd, H2 2017
Insomnia-Pipeline by Evotec AG, H2 2017
Insomnia-Pipeline by Grupo Ferrer Internacional SA, H2 2017
Insomnia-Pipeline by Heptares Therapeutics Ltd, H2 2017
Insomnia-Pipeline by Idorsia Ltd, H2 2017
Insomnia-Pipeline by Intec Pharma Ltd, H2 2017
Insomnia-Pipeline by Intra-Cellular Therapies Inc, H2 2017
Insomnia-Pipeline by Johnson & Johnson, H2 2017
Insomnia-Pipeline by Leading BioSciences Inc, H2 2017
Insomnia-Pipeline by Merck & Co Inc, H2 2017
Insomnia-Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Insomnia-Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Insomnia-Pipeline by Shionogi & Co Ltd, H2 2017
Insomnia-Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Insomnia-Pipeline by Yangtze River Pharmaceutical Group, H2 2017
Insomnia-Dormant Projects, H2 2017
Insomnia-Dormant Projects, H2 2017 (Contd..1), H2 2017
Insomnia-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Insomnia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *